Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology

Neurobiology of Aging

Volumn 35, Issue 9, 2014, Pages 2079-2090

  Laurent, Cyril ^a,b   Eddarkaoui, Sabiha ^a,b   Derisbourg, Maxime ^a,b   Leboucher, Antoine ^a,b   Demeyer, Dominique ^a,b   Carrier, Sébastien ^a,b   Schneider, Marion ^c   Hamdane, Malika ^a,b   Müller, Christa E ^c   Buée, Luc ^a,b,d   Blum, David ^a,b,d  

^a UNIV LILLE   (France)

^b JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^c UNIVERSITY OF BONN   (Germany)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer's disease; Caffeine; Caffeine metabolites; Tau; THY Tau22; Transgenic

Indexed keywords

CAFFEINE; EXCITATORY AMINO ACID TRANSPORTER 3; PARAXANTHINE; TAU PROTEIN; THEOBROMINE; THEOPHYLLINE; TRANSCRIPTION FACTOR NRF2;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN REGION; COFFEE; CONTROLLED STUDY; FOOD INTAKE; HIPPOCAMPUS; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SPATIAL MEMORY; TASK PERFORMANCE; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; MEMORY DISORDERS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN DEGRADATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; CAFFEINE; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MALE; MEMORY DISORDERS; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHORYLATION; PROTEOLYSIS; TAU PROTEINS;

EID: 84902082985     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.03.027     Document Type: Article

References (85)

1. Alzoubi K.H., Srivareerat M., Aleisa A.M., Alkadhi K.A. Chronic caffeine treatment prevents stress-induced LTP impairment: the critical role of phosphorylated CaMKII and BDNF. J.Mol. Neurosci. 2013, 49:11-20.
2. Arendash G.W., Schleif W., Rezai-Zadeh K., Jackson E.K., Zacharia L.C., Cracchiolo J.R., Shippy D., Tan J. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 2006, 142:941-952.
3. Arendash G.W., Mori T., Cao C., Mamcarz M., Runfeldt M., Dickson A., Rezai-Zadeh K., Tane J., Citron B.A., Lin X., Echeverria V., Potter H. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J.Alzheimer Dis. 2009, 17:661-680.
4. Belarbi K., Burnouf S., Fernandez-Gomez F.J., Laurent C., Lestavel S., Figeac M., Sultan A., Troquier L., Leboucher A., Caillierez R., Grosjean M.E., Demeyer D., Obriot H., Brion I., Barbot B., Galas M.C., Staels B., Humez S., Sergeant N., Schraen-Maschke S., Muhr-Tailleux A., Hamdane M., Buée L., Blum D. Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like tau pathology. Neurobiol. Dis. 2011, 42:486-494.
5. Bellucci A., Westwood A.J., Ingram E., Casamenti F., Goedert M., Spillantini M.G. Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am. J. Pathol. 2004, 165:1643-1652.
6. Blum D., Sandau U., Laurent C., Batalha V., Leboucher A., Hamdane M., Pasquier P., Boison D., Buée L., Lopes L.V. Adenosine receptors and Alzheimer's disease. Adenosine: A Key Link between Metabolism and Brain Activity 2013, 385-408. Springer, New York. S. Masino, D. Boison (Eds.).
7. Brothers H.M., Marchalant Y., Wenk G.L. Caffeine attenuates lipopolysaccharide-induced neuroinflammation. Neurosci. Lett. 2010, 480:97-100.
8. Braak H., Thal D.R., Ghebremedhin E., Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J.Neuropathol. Exp. Neurol. 2011, 70:960-969.
9. Burnouf S., Martire A., Derisbourg M., Laurent C., Belarbi K., Leboucher A., Fernandez-Gomez F.J., Troquier L., Eddarkaoui S., Grosjean M.E., Demeyer D., Muhr-Tailleux A., Buisson A., Sergeant N., Hamdane M., Humez S., Popoli P., Buée L., Blum D. NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a tau transgenic model. Aging Cell 2013, 12:11-23.
10. Cao C., Cirrito J.R., Lin X., Wang L., Verges D.K., Dickson A., Mamcarz M., Zhang C., Mori T., Arendash G.W., Holtzman D.M., Potter H. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J.Alzheimers Dis. 2009, 17:681-697.
11. Cao C., Loewenstein D.A., Lin X., Zhang C., Wang L., Duara R., Wu Y., Giannini A., Bai G., Cai J., Greig M., Schofield E., Ashok R., Small B., Potter H., Arendash G.W. High blood caffeine levels in MCI linked to lack of progression to dementia. J.Alzheimers Dis. 2012, 30:559-572.
12. Chen J.F., Chern Y. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies. Handb. Exp. Pharmacol. 2011, 200:267-310.
13. Corcoran N.M., Martin D., Hutter-Paier B., Windisch M., Nguyen T., Nheu L., Sundstrom L.E., Costello A.J., Hovens C.M. Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. J.Clin. Neurosci. 2010, 17:1025-1033.
14. Costenla A.R., Cunha R.A., de Mendonça A. Caffeine, adenosine receptors, and synaptic plasticity. J.Alzheimers Dis. 2010, 20(Suppl 1):S25-S34.
15. Currais A., Kato K., Canuet L., Ishii R., Tanaka T., Takeda M., Soriano S. Caffeine modulates tau phosphorylation and affects Akt signaling in postmitotic neurons. J.Mol. Neurosci. 2011, 43:326-332.
16. Dai S.S., Zhou Y.G., Li W., An J.H., Li P., Yang N., Chen X.Y., Xiong R.P., Liu P., Zhao Y., Shen H.Y., Zhu P.F., Chen J.F. Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury. J.Neurosci. 2010, 30:5802-5810.
17. Dall'Igna O.P., Porciúncula L.O., Souza D.O., Cunha R.A., Lara D.R. Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br. J. Pharmacol. 2003, 138:1207-1209.
18. Dall'Igna O.P., Fett P., Gomes M.W., Souza D.O., Cunha R.A., Lara D.R. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp. Neurol. 2007, 203:241-245.
19. Duarte J.M., Agostinho P.M., Carvalho R.A., Cunha R.A. Caffeine consumption prevents diabetes-induced memory impairment and synaptotoxicity in the hippocampus of NONcZNO10/LTJ mice. PLoS One 2012, 7:e21899.
20. Dumont J.M., Stack C., Elipenahli C., Jainuddin S., Gerges M., Starkova N.N., Yang L., Starkov A.A., Beal F. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J. 2011, 25:4063-4072.
21. Duyckaerts C., Bennecib M., Grignon Y., Uchihara T., He Y., Piette F., Hauw J.J. Modeling the relation between neurofibrillary tangles and intellectual status. Neurobiol. Aging 1997, 18:267-273.
22. Escartin C., Won S.J., Malgorn C., Auregan G., Berman A.E., Chen P.C., Déglon N., Johnson J.A., Suh S.W., Swanson R.A. Nuclear factor erythroid 2-related factor 2 facilitates neuronal glutathione synthesis by upregulating neuronal excitatory amino acid transporter 3 expression. J.Neurosci. 2011, 31:7392-7401.
23. Eskelinen M.H., Ngandu T., Tuomilehto J., Soininen H., Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J.Alzheimers Dis. 2009, 16:85-91.
24. Fredholm B.B., Bättig K., Holmén J., Nehlig A., Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 1999, 51:83-133.
25. Garwood C.J., Cooper J.D., Hanger D.P., Noble W. Anti-inflammatory impact of minocycline in a mouse model of tauopathy. Front. Psychiatry 2010, 12:136.
26. Georgiev V., Johansson B., Fredholm B.B. Long-term caffeine treatment leads to a decreased susceptibility to NMDA-induced clonic seizures in mice without changes in adenosine A1 receptor number. Brain Res. 1993, 612:271-277.
27. Giovannini M.G. The role of the extracellular signal-regulated kinase pathway in memory encoding. Rev. Neurosci. 2006, 17:619-634.
28. Gómez-Ruiz J.A., Leake D.S., Ames J.M. Invitro antioxidant activity of coffee compounds and their metabolites. J.Agric. Food Chem. 2007, 55:6962-6969.
29. Gorlovoy P., Larionov S., Pham T.T., Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J. 2009, 23:2502-2513.
30. Grober E., Dickson D., Sliwinski M.J., Buschke H., Katz M., Crystal H., Lipton R.B. Memory and mental status correlates of modified Braak staging. Neurobiol. Aging 1999, 20:573-579.
31. Guan J.S., Su S.C., Gao J., Joseph N., Xie Z., Zhou Y., Durak O., Zhang L., Zhu J.J., Clauser K.R., Carr S.A., Tsai L.H. Cdk5 is required for memory function and hippocampal plasticity via the cAMP signaling pathway. PLoS One 2011, 6:e25735.
32. Hamdane M., Sambo A.V., Delobel P., Bégard S., Violleau A., Delacourte A., Bertrand P., Benavides J., Buée L. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J.Biol. Chem. 2003, 278:34026-34034.
33. Han M.E., Kim H.J., Lee Y.S., Kim D.H., Choi J.T., Pan C.S., Yoon S., Baek S.Y., Kim B.S., Kim J.B., Oh S.O. Regulation of cerebrospinal fluid production by caffeine consumption. BMC Neurosci. 2009, 10:110.
34. Hébert S.S., Papadopoulou A.S., Smith P., Galas M.C., Planel E., Silahtaroglu A.N., Sergeant N., Buée L., De Strooper B. Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum. Mol. Genet. 2010, 19:3959-3969.
35. Heneka M.T., O'Banion M.K. Inflammatory processes in Alzheimer's disease. J.Neuroimmunol 2007, 184:69-91.
36. Khairnar A., Plumitallo A., Frau L., Schintu N., Morelli M. Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine ('ecstasy') in mouse brain. Neurotox. Res. 2010, 17:435-439.
37. Kaplan G.B., Greenblatt D.J., Leduc B.W., Thompson M.L., Shader R.I. Relationship of plasma and brain concentrations of caffeine and metabolites to benzodiazepine receptor binding and locomotor activity. J.Pharmacol. Exp. Ther. 1989, 248:1078-1083.
38. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N., LaFerla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J.Neurosci. 2005, 25:8843-8853.
39. Kovac A., Zilka N., Kazmerova Z., Cente M., Zilkova M., Novak M. Misfolded truncated protein τ induces innate immune response via MAPK pathway. J.Immunol. 2011, 187:2732-2739.
40. Kovacech B., Novak M. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease. Curr. Alzheimer Res. 2010, 7:708-716.
41. Lai K.O., Wong A.S., Cheung M.C., Xu P., Liang Z., Lok K.C., Xie H., Palko M.E., Yung W.H., Tessarollo L., Cheung Z.H., Ip N.Y. TrkB phosphorylation by Cdk5 is required for activity-dependent structural plasticity and spatial memory. Nat. Neurosci. 2012, 15:1506-1515.
42. Le Freche H., Brouillette J., Fernandez-Gomez F.J., Patin P., Caillierez R., Zommer N., Sergeant N., Buée-Scherrer V., Lebuffe G., Blum D., Buée L. Tau phosphorylation and sevoflurane anesthesia: an association to postoperative cognitive impairment. Anesthesiology 2012, 116:779-787.
43. Leboucher A., Laurent C., Fernandez-Gomez F.J., Burnouf S., Troquier L., Eddarkaoui S., Demeyer D., Caillierez R., Zommer N., Vallez E., Bantubungi K., Breton C., Pigny P., Buée-Scherrer V., Staels B., Hamdane M., Tailleux A., Buée L., Blum D. Detrimental effects of diet-induced obesity on τ pathology are independent of insulin resistance in τ transgenic mice. Diabetes 2013, 62:1681-1688.
44. Lindsay J., Laurin D., Verreault R., Hébert R., Helliwell B., Hill G.B., McDowell I. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol. 2002, 156:445-453.
45. Liu F., Grundke-Iqbal I., Iqbal K., Gong C.X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 2005, 22:1942-1950.
46. Lublin A., Isoda F., Patel H., Yen K., Nguyen L., Hajje D., Schwartz M., Mobbs C. FDA-approved drugs that protect mammalian neurons from glucose toxicity slow aging dependent on cbp and protect against proteotoxicity. PLoS One 2011, 6:e27762.
47. Luongo L., Guida F., Imperatore R., Napolitano F., Gatta L., Cristino L., Giordano C., Siniscalco D., Di Marzo V., Bellini G., Petrelli R., Cappellacci L., Usiello A., de Novellis V., Rossi F., Maione S. The A1 adenosine receptor as a new player in microglia physiology. Glia 2014, 62:122-132.
48. Maia, en de Mendonça A. Does caffeine intake protect from Alzheimer's disease?. Eur. J. Neurol. 2002, 9:377-382.
49. Marques S., Batalha V.L., Lopes L.V., Outeiro T.F. Modulating Alzheimer's disease through caffeine: a putative link to epigenetics. J.Alzheimer Dis. 2011, 24(Suppl 2):161-171.
50. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A 1985, 82:4245-4249.
51. Müller C.E., Jacobson K.A. Xanthines as adenosine receptor antagonists. Handb. Exp. Pharmacol. 2011, 200:151-199.
52. Nobre H.V., Cunha G.M., de Vasconcelos L.M., Magalhães H.I., Oliveira Neto R.N., Maia F.D., de Moraes M.O., Leal L.K., Viana G.S. Caffeine and CSC, adenosine A2A antagonists, offer neuroprotection against 6-OHDA-induced neurotoxicity in rat mesencephalic cells. Neurochem. Int. 2010, 56:51-58.
53. Novak M., Kabat J., Wischik C.M. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J. 1993, 12:365-370.
54. Orr A.G., Orr A.L., Li X.J., Gross R.E., Traynelis S.F. Adenosine A(2A) receptor mediates microglial process retraction. Nat Neurosci 2009, 12:872-878.
55. Papon M.A., El Khoury N.B., Marcouiller F., Julien C., Morin F., Bretteville A., Petry F.R., Gaudreau S., Amrani A., Mathews P.M., Hébert S.S., Planel E. Deregulation of protein phosphatase 2A and hyperphosphorylation of τ protein following onset of diabetes in NOD mice. Diabetes 2013, 62:609-617.
56. Planel E., Richter K.E., Nolan C.E., Finley J.E., Liu L., Wen Y., Krishnamurthy P., Herman M., Wang L., Schachter J.B., Nelson R.B., Lau L.F., Duff K.E. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J.Neurosci. 2007, 27:3090-3097.
57. Planel E., Bretteville A., Liu L., Virag L., Du A.L., Yu W.H., Dickson D.W., Whittington R.A., Duff K.E. Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J. 2009, 23:2595-2604.
58. Pohanka M., Dobes P. Caffeine inhibits acetylcholinesterase, but not butyrylcholinesterase. Int. J. Mol. Sci. 2013, 14:9873-9882.
59. Popoli P., Blum D., Martire A., Ledent C., Ceruti S., Abbracchio M.P. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog. Neurobiol. 2007, 81:331-348.
60. Postuma R.B., Lang A.E., Munhoz R.P., Charland K., Pelletier A., Moscovich M., Filla L., Zanatta D., Rios Romenets S., Altman R., Chuang R., Shah B. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012, 79:651-658.
61. Prasanthi J.R., Dasari B., Marwarha G., Larson T., Chen X., Geiger J.D., Ghribi O. Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. Free Radic. Biol. Med. 2010, 49:1212-1220.
62. Rebola N., Simões A.P., Canas P.M., Tomé A.R., Andrade G.M., Barry C.E., Agostinho P.M., Lynch M.A., Cunha R.A. Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J.Neurochem. 2011, 117:100-111.
63. Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 2011, 7:137-152.
64. Rissman R.A., Poon W.W., Blurton-Jones M., Oddo S., Torp R., Vitek M.P., LaFerla F.M., Rohn T.T., Cotman C.W. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J.Clin. Invest. 2004, 114:121-130.
65. Ritchie K., Carrière I., de Mendonca A., Portet F., Dartigues J.F., Rouaud O., Barberger-Gateau P., Ancelin M.L. The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology 2007, 69:536-545.
66. Rosenmann H., Grigoriadis N., Eldar-Levy H. Anovel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp. Neurol. 2008, 212:71-84.
67. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., Ashe K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
68. Schindowski K., Bretteville A., Leroy K., Bégard S., Brion J.P., Hamdane M., Buée L. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol. 2006, 169:599-616.
69. Sergeant N., Bretteville A., Hamdane M., Caillet-Boudin M.L., Grognet P., Bombois S., Blum D., Delacourte A., Pasquier F., Vanmechelen E., Schraen-Maschke S., Buée L. Biochemistry of tau in Alzheimer's disease and related neurological disorders. Expert Rev. Proteomics 2008, 5:207-224.
70. Simons S.B., Caruana D.A., Zhao M., Dudek S.M. Caffeine-induced synaptic potentiation in hippocampal CA2 neurons. Nat. Neurosci. 2011, 15:23-25.
71. Stoppelkamp S., Bell H.S., Palacios-Filardo J., Shewan D.A., Riedel G., Platt B. Invitro modelling of Alzheimer's disease: degeneration and cell death induced by viral delivery of amyloid and tau. Exp. Neurol. 2011, 229:226-237.
72. Tikh E.I., Fenton R.A., Chen J.F., Schwarzschild M.A., Dobson J.G. Adenosine A1 and A2A receptor regulation of protein phosphatase 2A in the murine heart. J.Cell. Physiol. 2008, 216:83-90.
73. Troquier L., Caillierez R., Burnouf S., Fernandez-Gomez F.J., Grosjean M.E., Zommer N., Sergeant N., Schraen-Maschke S., Blum D., Buee L. Targeting phospho-Ser422 by active tau immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr. Alzheimer Res. 2012, 9:397-405.
74. Van der Jeugd A., Vermarcke B., Blum D., Derisbourg M., Hamdane M., Buee L., Op de Beeck H., D'Hooge R. Progressive age-related cognitive decline in tau mice. J.Alzheimers Dis. 2013, 4:777-788.
75. Van Eersel J., Ke Y.D., Liu X., Delerue F., Kril J.J., Götz J., Ittner L.M. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc. Natl. Acad. Sci. U.S.A 2010, 107:13888-13893.
76. Van Gelder B.M., Buijsse B., Tijhuis M., Kalmijn S., Giampaoli S., Nissinen A., Kromhout D. Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur. J. Clin. Nutr. 2007, 61:226-232.
77. Vila-Luna S., Cabrera-Isidoro S., Vila-Luna L., Juárez-Díaz I., Bata-García J.L., Alvarez-Cervera F.J., Zapata-Vázquez R.E., Arankowsky-Sandoval G., Heredia-López F., Flores G., Góngora-Alfaro J.L. Chronic caffeine consumption prevents cognitive decline from young to middle age in rats, and is associated with increased length, branching, and spine density of basal dendrites in CA1 hippocampal neurons. Neuroscience 2012, 202:384-395.
78. Whittington R.A., Bretteville A., Dickler M.F., Planel E. Anesthesia and tau pathology. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 47:147-155.
79. Wostyn P., Van Dam D., Audenaert K., De Deyn P.P. Increased cerebrospinal fluid production as a possible mechanism underlying caffeine's protective effect against Alzheimer's disease. Int. J. Alzheimers Dis. 2011, 2011:617420.
80. Xu K., Xu Y.H., Chen J.F., Schwarzschild M.A. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience 2010, 167:475-481.
81. Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., Lee V.M. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
82. Zeitlin R., Patel S., Burgess S., Arendash G.W., Echeverria V. Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice. Brain Res. 2011, 1417:127-136.
83. Zilka N., Filipcik P., Koson P., Fialova L., Skrabana R., Zilkova M., Rolkova G., Kontsekova E., Novak M. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration invivo. FEBS Lett. 2006, 580:3582-3588.
84. Zilka N., Stozicka Z., Kovac A., Pilipcinec E., Bugos O., Novak M. Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J.Neuroimmunol. 2009, 209:16-25.
85. Zilka N., Kovacech B., Barath P., Kontsekova E., Novák M. The self-perpetuating tau truncation circle. Biochem. Soc. Trans. 2012, 40:681-686.